P/E ratio for AstraZeneca (AZN)
P/E ratio as of April 2024 (TTM): 37.9
According to AstraZeneca's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.869. At the end of 2022 the company had a P/E ratio of 64.0.
P/E ratio history for AstraZeneca from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 64.0 | -84.08% |
| 2021 | 402 | 880.4% |
| 2020 | 41.0 | -57.68% |
| 2019 | 96.8 | 116.68% |
| 2018 | 44.7 | 52.59% |
| 2017 | 29.3 | 48.32% |
| 2016 | 19.7 | -35.16% |
| 2015 | 30.4 | -57.6% |
| 2014 | 71.8 | 146.77% |
| 2013 | 29.1 | 205.99% |
| 2012 | 9.51 | 50.61% |
| 2011 | 6.32 | -23.44% |
| 2010 | 8.25 | -8.8% |
| 2009 | 9.04 | -7.42% |
| 2008 | 9.77 | -14.67% |
| 2007 | 11.4 | -17.47% |
| 2006 | 13.9 | -16.93% |
| 2005 | 16.7 | 2135.52% |
| 2004 | 0.7471 | -97.27% |
| 2003 | 27.3 | 27.75% |
| 2002 | 21.4 | -25.68% |
| 2001 | 28.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -72.60% | 🇺🇸 USA |
 Novartis NVS | 26.1 | -31.20% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -63.95% | 🇺🇸 USA |
 Abbott Laboratories ABT | 36.2 | -4.48% | 🇺🇸 USA |
 Eli Lilly LLY | 135 | 256.30% | 🇺🇸 USA |
 Sanofi SNY | 15.5 | -59.14% | 🇫🇷 France |
 Biogen BIIB | 11.3 | -70.11% | 🇺🇸 USA |
 Merck MRK | 72.0 | 90.17% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -70.14% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.8 | -68.94% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.